• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    SC 13G/A 1 enov13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ENOVIS CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 194014502 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 2,693,720 6. Shared Voting Power* 0 7. Sole Dispositive Power* 6,582,110 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,582,110 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 12.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: ENOVIS CORP Item 1(b) Address of Issuer's Principal Executive Offices: 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON, DELAWARE 19808 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 194014502 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. (2) [T. ROWE PRICE MID-CAP GROWTH FUND ]: T. ROWE PRICE MID-CAP GROWTH FUND, of which T. Rowe Price Investment Management, Inc. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. Rowe Price Investment Management, Inc. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE MID-CAP GROWTH FUND has an interest in 3,225,400 of the class reported herein representing 5.9% of the class. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2024 Signature: /s/ Armando Capasso Name & Title: Armando Capasso, Vice President 12/31/2023
    Get the next $ENOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Financials

    Live finance-specific insights

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Fourth Quarter and Full Year 2024 Results

      Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F

      2/26/25 6:01:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enovis Corporation

      10-Q - Enovis CORP (0001420800) (Filer)

      5/8/25 5:14:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enovis CORP (0001420800) (Filer)

      5/8/25 6:19:47 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Enovis Corporation

      DEF 14A - Enovis CORP (0001420800) (Filer)

      4/11/25 4:01:52 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shirley Brady was granted 829 shares, increasing direct ownership by 0.84% to 99,196 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/11/25 9:30:04 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Director Lalor Angela S was granted 589 shares, increasing direct ownership by 5% to 13,237 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/1/25 9:00:07 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) was granted 24,137 shares, increasing direct ownership by 76% to 55,983 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      3/11/25 9:00:16 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Enovis Corporation with a new price target

      JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

      10/3/24 7:29:21 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Enovis Corporation with a new price target

      JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

      6/13/24 7:06:52 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Stephens initiated coverage on Enovis Corporation with a new price target

      Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

      2/13/24 6:34:49 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enovis Corporation

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      11/14/24 1:28:31 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      4/5/24 12:21:51 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      2/14/24 10:04:36 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

      NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

      1/7/25 6:19:00 PM ET
      $ARCH
      $CART
      $CEIX
      $ENOV
      Coal Mining
      Energy
      Business Services
      Consumer Discretionary
    • Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

      WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

      9/9/24 3:50:00 PM ET
      $ENOV
      Industrial Specialties
      Health Care